And we finally identified the presence and spatial proximity of CD8+FoxP3+PD-1+ cells as potential biomarkers to predict the treatment response and immunotherapy-related survival of advanced NSCLC patients. This evidence concerns the gene FOXP3 and non-small cell lung carcinoma.